Contrastive multimodal learning significantly enhances survival prediction in grade 2/3 gliomas by effectively integrating histopathology, genomics, and clinical data. This annotation-free approach enables early risk stratification using routinely collected data and shows promise for informing personalized treatment decisions and clinical trial stratification.
Hua et al. (Thu,) studied this question.